SK4862000A3 - The use of 5-ht3 receptor antagonists - Google Patents
The use of 5-ht3 receptor antagonists Download PDFInfo
- Publication number
- SK4862000A3 SK4862000A3 SK486-2000A SK4862000A SK4862000A3 SK 4862000 A3 SK4862000 A3 SK 4862000A3 SK 4862000 A SK4862000 A SK 4862000A SK 4862000 A3 SK4862000 A3 SK 4862000A3
- Authority
- SK
- Slovakia
- Prior art keywords
- alosetron
- patients
- ibs
- pharmaceutically acceptable
- women
- Prior art date
Links
- 229940044551 receptor antagonist Drugs 0.000 title claims abstract description 12
- 239000002464 receptor antagonist Substances 0.000 title claims abstract description 12
- 102000035037 5-HT3 receptors Human genes 0.000 title claims abstract description 6
- 108091005477 5-HT3 receptors Proteins 0.000 title claims abstract description 6
- 208000002551 irritable bowel syndrome Diseases 0.000 claims abstract description 30
- 229960003550 alosetron Drugs 0.000 claims description 41
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 206010010774 Constipation Diseases 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 claims description 7
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 claims description 6
- 229960005343 ondansetron Drugs 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 102000005962 receptors Human genes 0.000 claims description 5
- 108020003175 receptors Proteins 0.000 claims description 5
- 229960003727 granisetron Drugs 0.000 claims description 4
- MFWNKCLOYSRHCJ-BTTYYORXSA-N granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- PWWDCRQZITYKDV-UHFFFAOYSA-N 1-benzyl-2-piperazin-1-ylbenzimidazole Chemical compound C1CNCCN1C1=NC2=CC=CC=C2N1CC1=CC=CC=C1 PWWDCRQZITYKDV-UHFFFAOYSA-N 0.000 claims description 3
- 229940113081 5 Hydroxytryptamine 3 receptor antagonist Drugs 0.000 claims description 3
- WUKZPHOXUVCQOR-UHFFFAOYSA-N N-(1-azabicyclo[2.2.2]octan-3-yl)-6-chloro-4-methyl-3-oxo-1,4-benzoxazine-8-carboxamide Chemical compound C1N(CC2)CCC2C1NC(=O)C1=CC(Cl)=CC2=C1OCC(=O)N2C WUKZPHOXUVCQOR-UHFFFAOYSA-N 0.000 claims description 3
- 229950005951 azasetron Drugs 0.000 claims description 3
- UKTAZPQNNNJVKR-KJGYPYNMSA-N chembl2368925 Chemical compound C1=CC=C2C(C(O[C@@H]3C[C@@H]4C[C@H]5C[C@@H](N4CC5=O)C3)=O)=CNC2=C1 UKTAZPQNNNJVKR-KJGYPYNMSA-N 0.000 claims description 3
- 229960003413 dolasetron Drugs 0.000 claims description 3
- MHNNVDILNTUWNS-XYYAHUGASA-N indisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CN(C[C@@H](C3)N4C)C)=NNC2=C1 MHNNVDILNTUWNS-XYYAHUGASA-N 0.000 claims description 3
- 229950007467 indisetron Drugs 0.000 claims description 3
- RWXRJSRJIITQAK-ZSBIGDGJSA-N itasetron Chemical compound C12=CC=CC=C2NC(=O)N1C(=O)N[C@H](C1)C[C@H]2CC[C@@H]1N2C RWXRJSRJIITQAK-ZSBIGDGJSA-N 0.000 claims description 3
- 229950007654 itasetron Drugs 0.000 claims description 3
- 229950009727 lerisetron Drugs 0.000 claims description 3
- NTHPAPBPFQJABD-LLVKDONJSA-N ramosetron Chemical compound C12=CC=CC=C2N(C)C=C1C(=O)[C@H]1CC(NC=N2)=C2CC1 NTHPAPBPFQJABD-LLVKDONJSA-N 0.000 claims description 3
- 229950001588 ramosetron Drugs 0.000 claims description 3
- 229960003688 tropisetron Drugs 0.000 claims description 3
- UIVFDCIXTSJXBB-ITGUQSILSA-N tropisetron Chemical compound C1=CC=C[C]2C(C(=O)O[C@H]3C[C@H]4CC[C@@H](C3)N4C)=CN=C21 UIVFDCIXTSJXBB-ITGUQSILSA-N 0.000 claims description 3
- FLZQKRKHLSUHOR-UHFFFAOYSA-N alosetron Chemical group CC1=NC=N[C]1CN1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FLZQKRKHLSUHOR-UHFFFAOYSA-N 0.000 claims 5
- FEROPKNOYKURCJ-ZDUSSCGKSA-N 4-amino-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-5-chloro-2-methoxybenzamide Chemical compound COC1=CC(N)=C(Cl)C=C1C(=O)N[C@@H]1C(CC2)CCN2C1 FEROPKNOYKURCJ-ZDUSSCGKSA-N 0.000 claims 2
- NCNFDKWULDWJDS-OAHLLOKOSA-N cilansetron Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C=3N4CCCC=3C=CC=2)=C4CC1 NCNFDKWULDWJDS-OAHLLOKOSA-N 0.000 claims 2
- 229960002099 cilansetron Drugs 0.000 claims 2
- JSWZEAMFRNKZNL-UHFFFAOYSA-N alosetron Chemical compound N1C=NC(CN2C(C3=C(N(C4=CC=CC=C43)C)CC2)=O)=C1C JSWZEAMFRNKZNL-UHFFFAOYSA-N 0.000 description 37
- 239000000902 placebo Substances 0.000 description 17
- 229940068196 placebo Drugs 0.000 description 17
- 230000006872 improvement Effects 0.000 description 13
- 208000004998 Abdominal Pain Diseases 0.000 description 10
- 208000002193 Pain Diseases 0.000 description 10
- 210000001072 colon Anatomy 0.000 description 10
- 230000036407 pain Effects 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- 239000000203 mixture Substances 0.000 description 9
- 239000003814 drug Substances 0.000 description 7
- 150000003890 succinate salts Chemical class 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- -1 (-) - indol-3-yl Chemical group 0.000 description 5
- 206010012735 Diarrhoea Diseases 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000002354 daily effect Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 229940079593 drug Drugs 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 210000000664 rectum Anatomy 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- GZXONPGTMHLBKQ-UTONKHPSSA-N 2,3-dihydroindol-1-yl-[(5r)-4,5,6,7-tetrahydro-3h-benzimidazol-5-yl]methanone;hydrochloride Chemical compound Cl.C1CC2=CC=CC=C2N1C(=O)[C@H]1CC(NC=N2)=C2CC1 GZXONPGTMHLBKQ-UTONKHPSSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000010972 statistical evaluation Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- LNETULKMXZVUST-UHFFFAOYSA-N 1-naphthoic acid Chemical class C1=CC=C2C(C(=O)O)=CC=CC2=C1 LNETULKMXZVUST-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical class C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1
- YPELFRMCRYSPKZ-UHFFFAOYSA-N 4-amino-5-chloro-2-ethoxy-N-({4-[(4-fluorophenyl)methyl]morpholin-2-yl}methyl)benzamide Chemical compound CCOC1=CC(N)=C(Cl)C=C1C(=O)NCC1OCCN(CC=2C=CC(F)=CC=2)C1 YPELFRMCRYSPKZ-UHFFFAOYSA-N 0.000 description 1
- MJCKISCWHDATBN-UHFFFAOYSA-N 4-amino-5-chloro-n-[(1-ethyl-4,5-dihydroimidazol-2-yl)methyl]-2-methoxybenzamide Chemical compound CCN1CCN=C1CNC(=O)C1=CC(Cl)=C(N)C=C1OC MJCKISCWHDATBN-UHFFFAOYSA-N 0.000 description 1
- DHSSDEDRBUKTQY-UHFFFAOYSA-N 6-prop-2-enyl-4,5,7,8-tetrahydrothiazolo[4,5-d]azepin-2-amine Chemical compound C1CN(CC=C)CCC2=C1N=C(N)S2 DHSSDEDRBUKTQY-UHFFFAOYSA-N 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 150000000994 L-ascorbates Chemical class 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000000114 Pain Threshold Diseases 0.000 description 1
- 206010033372 Pain and discomfort Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 229940022701 alosetron 1 mg Drugs 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229950002371 lintopride Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 description 1
- 229960001785 mirtazapine Drugs 0.000 description 1
- 229960004085 mosapride Drugs 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- KOYCUQMOCJHRJC-MLOZCBHJSA-N n-[(1s,5r)-3,9-dimethyl-3,9-diazabicyclo[3.3.1]nonan-7-yl]-1h-indazole-3-carboxamide;hydron;dichloride Chemical compound Cl.Cl.C1=CC=C2C(C(=O)NC3C[C@H]4CN(C[C@@H](C3)N4C)C)=NNC2=C1 KOYCUQMOCJHRJC-MLOZCBHJSA-N 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000037040 pain threshold Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000007847 structural defect Effects 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical class NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229950008418 talipexole Drugs 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9721139.5A GB9721139D0 (en) | 1997-10-07 | 1997-10-07 | Medicaments |
| PCT/EP1998/006278 WO1999017755A2 (fr) | 1997-10-07 | 1998-10-05 | Medicaments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK4862000A3 true SK4862000A3 (en) | 2001-01-18 |
Family
ID=10820099
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK486-2000A SK4862000A3 (en) | 1997-10-07 | 1998-10-05 | The use of 5-ht3 receptor antagonists |
Country Status (36)
| Country | Link |
|---|---|
| US (3) | US6284770B1 (fr) |
| EP (1) | EP1021174A2 (fr) |
| JP (1) | JP2001518495A (fr) |
| KR (1) | KR20010015707A (fr) |
| CN (1) | CN1281357A (fr) |
| AP (1) | AP2000001785A0 (fr) |
| AR (1) | AR017296A1 (fr) |
| AU (1) | AU750818B2 (fr) |
| BR (1) | BR9812886A (fr) |
| CA (1) | CA2305751A1 (fr) |
| CO (1) | CO5011096A1 (fr) |
| DZ (1) | DZ2618A1 (fr) |
| EA (1) | EA003184B1 (fr) |
| EE (1) | EE200000214A (fr) |
| GB (1) | GB9721139D0 (fr) |
| GT (1) | GT199800157A (fr) |
| HN (1) | HN1998000155A (fr) |
| HR (1) | HRP20000198A2 (fr) |
| HU (1) | HUP0003750A3 (fr) |
| ID (1) | ID23874A (fr) |
| IL (1) | IL135398A0 (fr) |
| IS (1) | IS5425A (fr) |
| MA (1) | MA26549A1 (fr) |
| NO (1) | NO20001776L (fr) |
| NZ (1) | NZ503698A (fr) |
| PA (1) | PA8461101A1 (fr) |
| PE (1) | PE120299A1 (fr) |
| PL (1) | PL340337A1 (fr) |
| SK (1) | SK4862000A3 (fr) |
| SV (1) | SV1998000122A (fr) |
| TN (1) | TNSN98179A1 (fr) |
| TR (1) | TR200000913T2 (fr) |
| UY (1) | UY25200A1 (fr) |
| WO (1) | WO1999017755A2 (fr) |
| YU (1) | YU20600A (fr) |
| ZA (1) | ZA989061B (fr) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9721139D0 (en) | 1997-10-07 | 1997-12-03 | Glaxo Group Ltd | Medicaments |
| US7767203B2 (en) * | 1998-08-07 | 2010-08-03 | Ganeden Biotech, Inc. | Methods for the dietary management of irritable bowel syndrome and carbohydrate malabsorption |
| US6136807A (en) * | 1998-11-10 | 2000-10-24 | 3M Innovative Properties Company | Composition for the transdermal delivery of lerisetron |
| EP1090638A1 (fr) * | 1999-10-08 | 2001-04-11 | Sanofi-Synthelabo | Utilisation de (R)-zacopride ou d'un de ses sels dans la fabrication d'un médicament pour le traitement de l'apnée du sommeil |
| TWI263496B (en) * | 1999-12-10 | 2006-10-11 | Novartis Ag | Pharmaceutical combinations and their use in treating gastrointestinal disorders |
| DE10015783C2 (de) * | 2000-03-30 | 2003-12-04 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System zur Abgabe von Lerisetron und seine Verwendung |
| EP1284732A2 (fr) * | 2000-05-18 | 2003-02-26 | Glaxo Group Limited | Methode de traitement de la dyspepsie fonctionnelle |
| US6566369B2 (en) | 2000-07-26 | 2003-05-20 | Solvay Pharmaceuticals Gmbh | Medicament containing cilansetron for the treatment of non-obstipative male irritable bowel syndrome patients |
| AR028970A1 (es) * | 2000-07-26 | 2003-05-28 | Solvay Pharm Gmbh | USO DE CILANSETRON O DE SUS SALES POR ADICIoN DE A CIDOS Y/O SOLVATOS FARMACOLoGICAMENTE COMPATIBLES PARA LA OBTENCIoN DE PREPARADOS FARMACEUTICOS PARA EL TRATAMIENTO Y/O LA PROFILAXIS DEL SíNDROME DEL INTESTINO IRRITABLE |
| AU2001288564A1 (en) * | 2000-09-06 | 2002-03-22 | Glaxo Group Limited | 5-hydroxytryptamine receptor gene polymorphisms and response to treatment |
| GB0216027D0 (en) * | 2002-07-10 | 2002-08-21 | Arachnova Therapeutics Ltd | New therapeutic use |
| US20040048874A1 (en) * | 2001-05-22 | 2004-03-11 | Bardsley Hazel Judith | New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine |
| PT2266558T (pt) * | 2001-06-07 | 2017-07-21 | Analgesic Neuropharmaceuticals Llc | Tratamento da dor neuropática com o antagonista dos recetores de n-metil-d-aspartato (nmda) dextrometorfano |
| US7045549B2 (en) | 2001-11-08 | 2006-05-16 | The Board Of Trustees Of The Leland Stanford Jr. University | Treatment of symptoms associated with irritable bowel syndrome |
| ES2281646T3 (es) * | 2002-01-18 | 2007-10-01 | Aryx Therapeutics | Antagonistas del receptor 5-ht3 y procedimientos de utilizacion. |
| DE60326585D1 (de) * | 2002-07-10 | 2009-04-23 | Dynogen Pharmaceuticals Inc | 4-(2-fluorophenyl)-6-methyl-2(1-piperazinyl)thieno(2,3-d) pyrimidin bei der behandlung von funktionalen darmstörungen |
| DE10232750A1 (de) * | 2002-07-18 | 2004-02-05 | Basf Ag | Verfahren zur Herstellung von macrocyclischen Ketonen durch Dieckmann-Kondensation in der Gasphase |
| JP4399862B2 (ja) * | 2002-08-09 | 2010-01-20 | 味の素株式会社 | 腸疾患および内臓痛の治療薬 |
| US20030187017A1 (en) * | 2002-11-14 | 2003-10-02 | Mangel Allen Wayne | Method for treating functional dyspepsia |
| AU2004204825B2 (en) * | 2003-01-13 | 2007-07-19 | Dynogen Pharmaceuticals, Inc. | Method of treating functional bowel disorders |
| CA2512022A1 (fr) * | 2003-01-13 | 2004-07-29 | Dynogen Pharmaceuticals, Inc. | Methode pour traiter des nausees, des vomissements, des haut-le-coeur ou une association de ces symptomes |
| JO2735B1 (en) | 2003-01-30 | 2013-09-15 | هيلسين هيلث كير أس ايه. | Liquid pharmaceutical formations of balloonosterone |
| ZA200409537B (en) | 2003-01-31 | 2006-10-25 | Yamanouchi Pharma Co Ltd | Stable solid medicinal composition for oral administration |
| CA2550886A1 (fr) * | 2003-12-16 | 2005-06-30 | Teva Pharmaceutical Industries Ltd. | Formes polymorphiques de la base du tegaserod et des sels de celui-ci |
| JP3763360B2 (ja) * | 2004-01-30 | 2006-04-05 | アステラス製薬株式会社 | 下痢型過敏性腸症候群治療剤 |
| US7358270B2 (en) | 2004-01-30 | 2008-04-15 | Astellas Pharma Inc. | Treating agent for irritable bowel syndrome |
| WO2005073220A1 (fr) * | 2004-01-30 | 2005-08-11 | Yamanouchi Pharmaceutical Co., Ltd. | Remede contre le syndrome du colon irritable avec diarrhee |
| MXPA05009025A (es) * | 2004-01-30 | 2006-04-27 | Astellas Pharma Inc | Agentes de tratamiento para el sindrome de intestino delgado irritado con diarrea predominante. |
| WO2005076824A2 (fr) * | 2004-02-03 | 2005-08-25 | The Regents Of The University Of California | Methodes de traitement du syndrome du colon irritable |
| JP4559749B2 (ja) * | 2004-02-16 | 2010-10-13 | あすか製薬株式会社 | ピペラジニルピリジン誘導体 |
| EP1724267B1 (fr) * | 2004-02-26 | 2013-11-06 | ASKA Pharmaceutical Co., Ltd. | Derive de pyrimidine |
| JP2006028028A (ja) * | 2004-07-12 | 2006-02-02 | Teikoku Medix Kk | 経口医薬組成物 |
| US20060293309A1 (en) * | 2005-03-28 | 2006-12-28 | Dynogen Pharmaceuticals, Inc. | Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors |
| ATE495171T1 (de) * | 2005-06-07 | 2011-01-15 | Theravance Inc | Benzimidazoloncarbonsäureamidverbindungen als agonisten des 5-ht4-rezeptors |
| WO2007000046A1 (fr) * | 2005-06-27 | 2007-01-04 | Holburn Biomedical Corporation | Methodes de diagnostic de maladie intestinale fonctionnelle |
| JP4632204B2 (ja) * | 2005-09-21 | 2011-02-16 | アステラス製薬株式会社 | 下痢型過敏性腸症候群治療剤 |
| CA2642610A1 (fr) * | 2006-02-20 | 2007-08-30 | Astellas Pharma Inc. | Derive d'amine ou sel de celui-ci |
| US7601856B2 (en) | 2006-07-27 | 2009-10-13 | Wyeth | Benzofurans as potassium ion channel modulators |
| WO2009053733A2 (fr) | 2007-10-24 | 2009-04-30 | Generics [Uk] Limited | Nouvelles formes cristallines |
| WO2009053750A2 (fr) | 2007-10-24 | 2009-04-30 | Generics [Uk] Limited | Nouvelles formes cristallines et amorphes |
| WO2009053732A1 (fr) | 2007-10-24 | 2009-04-30 | Generics [Uk] Limited | Nouveau sel |
| WO2009053754A2 (fr) | 2007-10-24 | 2009-04-30 | Generics [Uk] Limited | Nouvelles formes cristallines |
| US8734867B2 (en) | 2007-12-28 | 2014-05-27 | Liveleaf, Inc. | Antibacterial having an extract of pomegranate combined with hydrogen peroxide |
| MY172676A (en) | 2009-03-04 | 2019-12-10 | Liveleaf Inc | Method and material for site activated complexing of biologic molecules |
| JP5836264B2 (ja) | 2009-04-29 | 2015-12-24 | ガネーデン バイオテック インコーポレイテッド | 不活性化細菌細胞製剤 |
| JP5741433B2 (ja) * | 2009-06-30 | 2015-07-01 | アステラス製薬株式会社 | 緩解期の炎症性腸疾患患者における排便異常治療剤 |
| JP5938886B2 (ja) * | 2010-12-14 | 2016-06-22 | アステラス製薬株式会社 | 活動期の炎症性腸疾患患者における排便異常治療剤 |
| US8722040B2 (en) | 2011-06-24 | 2014-05-13 | Liveleaf, Inc. | Site-activated binding systems that selectively increase the bioactivity of phenolic compounds at target sites |
| US9192635B2 (en) | 2011-06-24 | 2015-11-24 | Liveleaf, Inc. | Method of treating damaged mucosal or gastrointestinal tissue by administering a composition comprising a mixture of pomegranate and green tea extracts and releasably bound hydrogen peroxide |
| US20120329736A1 (en) * | 2011-06-24 | 2012-12-27 | Huang Alexander L | Treatment for gastrointestinal disorders using a selective, site-activated binding system |
| HUE030811T2 (hu) * | 2011-10-18 | 2017-05-29 | Helsinn Healthcare Sa | Netupitant és palonosetron terápiás kombinációi |
| KR20200065113A (ko) * | 2012-09-05 | 2020-06-08 | 체이스 파마슈티칼스 코포레이션 | 항콜린 신경보호 조성물 및 그 방법 |
| US8716351B1 (en) | 2012-12-23 | 2014-05-06 | Liveleaf, Inc. | Methods of treating gastrointestinal spasms |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0254584B1 (fr) * | 1986-07-25 | 1992-10-07 | Beecham Group Plc | Composés azabicycliques, procédé pour leur préparation et leur utilisation pharmaceutique |
| GB8806990D0 (en) * | 1988-03-23 | 1988-04-27 | Beecham Group Plc | Novel compounds |
| GB8701022D0 (en) | 1987-01-19 | 1987-02-18 | Beecham Group Plc | Treatment |
| EP0306323B1 (fr) * | 1987-09-03 | 1994-09-21 | Glaxo Group Limited | Dérivés de lactames |
| DE3850742T2 (de) * | 1987-11-04 | 1994-10-27 | Beecham Group Plc | Neue 4-Oxobenzotriazine und 4-Oxochinazoline. |
| US5116984A (en) | 1988-04-07 | 1992-05-26 | Glaxo Group Limited | Imidazole derivatives |
| GB8814277D0 (en) * | 1988-06-16 | 1988-07-20 | Glaxo Group Ltd | Chemical compounds |
| NZ230068A (en) * | 1988-07-29 | 1991-07-26 | Dainippon Pharmaceutical Co | Indazole-3-carboxylic acid esters and amides of diaza compounds having 6,7, or 8 ring members: preparatory processes and pharmaceutical compositions |
| GB8820650D0 (en) * | 1988-09-01 | 1988-10-05 | Glaxo Group Ltd | Medicaments |
| GB8823980D0 (en) | 1988-10-13 | 1988-11-23 | Glaxo Group Ltd | Chemical compounds |
| GB8829079D0 (en) * | 1988-12-13 | 1989-01-25 | Beecham Group Plc | Novel compounds |
| GB8904551D0 (en) * | 1989-02-28 | 1989-04-12 | Glaxo Group Ltd | Chemical compounds |
| EP0387431A1 (fr) * | 1989-03-14 | 1990-09-19 | Beecham Group Plc | Dérivés d'imidazole, procédés de leur préparation et leur application comme produits pharmaceutiques |
| GB9020927D0 (en) | 1990-09-26 | 1990-11-07 | Beecham Group Plc | Pharmaceuticals |
| GB9027098D0 (en) | 1990-12-13 | 1991-02-06 | Beecham Group Plc | Pharmaceuticals |
| GB9027487D0 (en) | 1990-12-19 | 1991-02-06 | Beecham Group Plc | Pharmaceuticals |
| EP0566609A1 (fr) | 1991-01-09 | 1993-10-27 | Smithkline Beecham Plc | Derives azabicydiques et azatricydiques, leurs procedes et intermediaires de preparation et compositions pharmaceutiques les contenant |
| GB9214184D0 (en) * | 1992-07-03 | 1992-08-12 | Smithkline Beecham Plc | Pharmaceuticals |
| GB9721139D0 (en) * | 1997-10-07 | 1997-12-03 | Glaxo Group Ltd | Medicaments |
-
1997
- 1997-10-07 GB GBGB9721139.5A patent/GB9721139D0/en not_active Ceased
-
1998
- 1998-10-05 PL PL98340337A patent/PL340337A1/xx unknown
- 1998-10-05 ID IDW20000654A patent/ID23874A/id unknown
- 1998-10-05 SK SK486-2000A patent/SK4862000A3/sk unknown
- 1998-10-05 IL IL13539898A patent/IL135398A0/xx unknown
- 1998-10-05 CN CN98811899A patent/CN1281357A/zh active Pending
- 1998-10-05 US US09/529,050 patent/US6284770B1/en not_active Expired - Lifetime
- 1998-10-05 MA MA25279A patent/MA26549A1/fr unknown
- 1998-10-05 WO PCT/EP1998/006278 patent/WO1999017755A2/fr not_active Ceased
- 1998-10-05 ZA ZA9809061A patent/ZA989061B/xx unknown
- 1998-10-05 PA PA19988461101A patent/PA8461101A1/es unknown
- 1998-10-05 PE PE1998000940A patent/PE120299A1/es not_active Application Discontinuation
- 1998-10-05 KR KR1020007003739A patent/KR20010015707A/ko not_active Withdrawn
- 1998-10-05 TR TR2000/00913T patent/TR200000913T2/xx unknown
- 1998-10-05 HR HR20000198A patent/HRP20000198A2/hr not_active Application Discontinuation
- 1998-10-05 EE EEP200000214A patent/EE200000214A/xx unknown
- 1998-10-05 YU YU20600A patent/YU20600A/sh unknown
- 1998-10-05 AU AU96293/98A patent/AU750818B2/en not_active Ceased
- 1998-10-05 NZ NZ503698A patent/NZ503698A/xx unknown
- 1998-10-05 TN TNTNSN98179A patent/TNSN98179A1/fr unknown
- 1998-10-05 AR ARP980104959A patent/AR017296A1/es not_active Application Discontinuation
- 1998-10-05 EP EP98950103A patent/EP1021174A2/fr not_active Withdrawn
- 1998-10-05 HU HU0003750A patent/HUP0003750A3/hu unknown
- 1998-10-05 AP AP2000001785A patent/AP2000001785A0/xx unknown
- 1998-10-05 JP JP2000514627A patent/JP2001518495A/ja active Pending
- 1998-10-05 CA CA002305751A patent/CA2305751A1/fr not_active Abandoned
- 1998-10-05 EA EA200000299A patent/EA003184B1/ru not_active IP Right Cessation
- 1998-10-05 BR BR9812886-8A patent/BR9812886A/pt not_active IP Right Cessation
- 1998-10-06 CO CO98057956A patent/CO5011096A1/es unknown
- 1998-10-06 SV SV1998000122A patent/SV1998000122A/es unknown
- 1998-10-06 HN HN1998000155A patent/HN1998000155A/es unknown
- 1998-10-06 DZ DZ980228A patent/DZ2618A1/fr active
- 1998-10-07 GT GT199800157A patent/GT199800157A/es unknown
- 1998-10-07 UY UY25200A patent/UY25200A1/es not_active Application Discontinuation
-
2000
- 2000-03-31 IS IS5425A patent/IS5425A/is unknown
- 2000-04-06 NO NO20001776A patent/NO20001776L/no not_active Application Discontinuation
-
2001
- 2001-04-13 US US09/834,717 patent/US6429209B2/en not_active Expired - Fee Related
-
2002
- 2002-06-10 US US10/166,401 patent/US6593336B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK4862000A3 (en) | The use of 5-ht3 receptor antagonists | |
| TWI389689B (zh) | 氟利本西林（ｆｌｉｂａｎｓｅｒｉｎ）於治療停經前性慾疾病之用途 | |
| DE602004005814T2 (de) | Verfahren zur behandlung von übelkeit, erbrechen, würgereiz oder jede kombination daraus | |
| KR100469029B1 (ko) | 세로토닌재흡수억제제의위장효과를극복하기위한5ht4수용체길항제의용도 | |
| ITMI941048A1 (it) | Uso di antagonisti degli oppiacei e di sali di calcio per la preparazione di medicamenti per il trattamento di forme patologiche endorfino-mediate | |
| SK281603B6 (sk) | Použitie 5ht3 antagonistu na prípravu farmaceutickej zmesi na liečenie fibromyalgie | |
| EA030145B1 (ru) | Комбинации агонистов бета-3-адренергических рецепторов и антагонистов мускариновых рецепторов для лечения гиперактивности мочевого пузыря | |
| CA2845039A1 (fr) | Combinaisons d'un agoniste de recepteur 5-ht4 et d'un inhibiteur de pde4 pour utilisation en therapie | |
| EP1276476A2 (fr) | Utilisation d'agents bradycardiques dans le traitement de maladies myocardiaques accompagnees d'hypertrophie et nouvelles combinaisons pharmaceutiques | |
| SK4542002A3 (en) | Synergistic combinations of an NK1 receptor antagonist and a GABA structural analog | |
| WO2021023877A2 (fr) | Compositions et méthodes de traitement de troubles dépendant des œstrogènes | |
| US5155126A (en) | Treatment of central nervous system disorders with pyrazole, pyrrole and triazole angiotensin-II receptor antagonists | |
| CA2362918A1 (fr) | Procedes et compositions pour le traitement de la dyserection | |
| EA000531B1 (ru) | Активное вещество при производстве фармацевтического препарата для лечения травматического повреждения головного мозга | |
| US4312879A (en) | Clonidine and lofexidine as antidiarrheal agents | |
| RU2181047C2 (ru) | Способ ингибирования состояний, ассоциированных с брадикинином | |
| DE3904795C2 (de) | Pharmazeutisches Präparat und dessen Verwendung | |
| US4363809A (en) | Organic compounds | |
| CZ2001150A3 (cs) | Lék pro léčbu psychóz nebo jiných neuropsychiatrických příznaků u pacientů s Alzheimerovou chorobou | |
| CZ20001259A3 (cs) | Farmaceutický prostředek | |
| US4904673A (en) | Agent for treating bradycardia and bradyarrhythmia | |
| RU2761219C2 (ru) | Терапевтическое средство от расстройств, связанных с употреблением алкоголя | |
| MXPA00003375A (en) | Medicaments | |
| DE3705220A1 (de) | Mittel zur behandlung von coronarerkrankungen oder organischem hirnsyndrom | |
| JPH07503968A (ja) | ３，５−ジアミノ−６−（２，３−ジクロロフェニル）−１，２，４−トリアジンの浮腫および痛みの治療のための使用 |